Skip to content

Arcus Biosciences RCUS Shares (Diluted)

Shares (Diluted) at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
107.7M-3.1%
AbbVie logo
AbbVieABBV
1.8B+0.1%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
88.7M+0.4%
Incyte logo
IncyteINCY
206.8M+4.4%
Erasca, Inc. logo
Erasca, Inc.ERAS
304.3M+7.4%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
1B+20.4%

Other financials

Income statement

See full
Revenue$17.0M-39.3%
Operating income-$134.0M-9.8%
Net income-$128.0M-14.3%
EPS (diluted)-$1.02+10.5%

Balance sheet

See full
Cash & equivalents$201.0M+4.7%
Total debt$113.0M+88.3%
Total equity$524.0M-1.3%
Total assets$997.0M-13.8%

Cash flow

See full
Operating cash flow-$138.0M-4.5%
CapEx--100%
Free cash flow-$138.0M-3.8%

Valuation

See full
Market cap$3.54B+226%
Enterprise value$3.46B+275%
P/S15×+7.3×

Profitability

See full
Operating margin-168.6%-52.7pp
Net margin-156.4%-47.5pp
FCF margin-207.2%

Returns & leverage

See full
Return on equity-70%+8.4pp
Debt / equity0.2×+0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcus Biosciences's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcus Biosciences's shares (diluted)?
Arcus Biosciences (RCUS) reported shares (diluted) of 125.4M in Q1 2026.
How has Arcus Biosciences's shares (diluted) changed year-over-year?
Arcus Biosciences's shares (diluted) increased by 27.4% year-over-year, from 98.4M to 125.4M.
What is the long-term trend for Arcus Biosciences's shares (diluted)?
Over 4 years (2021 to 2025), Arcus Biosciences's shares (diluted) has grown at a 10.5% compound annual growth rate (CAGR), from 280.9M to 418.8M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.